The continuous glucose monitoring (CGM) market has experienced strong but slowing growth in the U.S. blood glucose monitoring sector. Valued at over $6 billion in 2024, the market is only projected to grow at a compound annual growth rate (CAGR) of roughly 2% to surpass $7 billion by 2031. At the same time, the technologically inferior flash glucose monitoring (FGM) device market has grown by 45% over the last 3 years and is expected to nearly double by 2031. This remarkable growth highlights the growing relevance of FGM, even amid the strong presence of CGMs.
This article explores key trends and insights from the recently published U.S. Diabetes Monitoring, Treatment, and Drug Delivery Market Report.
Understanding Continuous & Flash Glucose Monitoring
Glucose monitoring technology has been transformative for diabetic individuals, especially those on insulin therapy who require frequent blood glucose readings. These devices allow for precise, real-time tracking by measuring interstitial glucose levels. Continuous glucose monitoring systems use a sensor implanted under the skin to continuously transmit glucose data to a receiver, providing essential support for diabetes management. As technology evolves, CGM systems are becoming even more accurate, user-friendly, and convenient, with innovations such as improved sensor accuracy, reduced reliance on fingerstick calibration, and optimized sensor placements for better glucose readings.
In contrast, flash glucose monitoring is a hybrid of CGM and blood glucose monitoring (BGM). Flash glucose monitoring systems continuously measure interstitial glucose levels but require users to manually scan the sensor to obtain a reading.
Drivers of FGM Market Growth in the Era of CGM
FGM’s steady market growth can largely be attributed to its more affordable cost structure compared to CGMs. The sensors and readers for FGM are significantly less expensive, making them a viable option for patients who don’t need the continuous, real-time glucose tracking that CGMs offer. For individuals with less frequent insulin needs, FGM provides an accessible and cost-effective alternative.
As of 2024, there are approximately 28 million diagnosed diabetics in the United States, a number expected to grow steadily, driven in part by the increasing prevalence of obesity. Individuals who are obese are at a significantly higher risk of developing type 2 diabetes, due to the body’s reduced ability to produce insulin as insulin resistance sets in. This growing diabetic population will continue to fuel the demand for glucose-monitoring products, ensuring long-term market expansion.
Market Implications
As the only current player in the FGM market, Abbott has been able to maintain a strong grasp of the price-sensitive consumer segment with their FreeStyle Libre FGM system. At the same time, their FreeStyle Libre 3 continuous glucose monitoring system has led to them holding the second-largest share of the CGM market as well. Other innovation-driven market leaders in the continuous glucose monitoring market like Dexcom and Medtronic with their G7 and Guardian™ CGM systems will ensure the sector stays competitive. However, a slowdown in innovation within the CGM market could spark price competition, potentially decreasing demand for FGM as the average sales prices for CGM drop.
Future of The Continuous & Flash Glucose Monitoring Markets
Both the CGM and FGM markets are positioned for sustained growth, driven by the rising demand for advanced diabetes management solutions. While CGM will remain the dominant force in glucose monitoring, the rapid expansion of FGM underscores its value as a more affordable option for individuals who do not require constant real-time monitoring. The increasing prevalence of diabetes, influenced by demographic and lifestyle factors, will fuel further market expansion, ensuring that both CGM and FGM technologies continue to evolve to meet patient needs.
For more detailed insights into market trends, growth projections, and strategic opportunities, explore our 2025 U.S. Diabetes Monitoring, Treatment and Drug Delivery Market Report.
